Mannitol Baxter

Mannitol, the active ingredient in Mannitol Baxter, is an osmotic diuretic presented as a solution for injection for intravenous use. It reduces elevated intracranial pressure, supports renal function in acute kidney injury, and assists in intraocular pressure management during glaucoma surgery.

GNH USA supplies Mannitol Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality and regulatory compliance.

Mannitol is employed in clinical situations that require osmotic diuresis or pressure reduction.

- Elevated intracranial pressure: lowers brain pressure by drawing fluid from cerebral tissue into the vascular compartment. - Oliguric renal failure: promotes urine output to assist renal clearance when kidney function is compromised. - Acute kidney injury: facilitates diuresis to help manage fluid overload and improve renal perfusion. - Intraocular pressure during glaucoma surgery: reduces eye pressure to improve surgical conditions and outcomes.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate discomfort often reported during infusion. - Nausea or vomiting: gastrointestinal upset related to rapid osmotic shifts. - Electrolyte disturbances: transient changes in sodium, potassium, or chloride levels. - Hypotension: drop in blood pressure due to intravascular volume expansion.

Serious or Rare Side Effects: - Acute renal failure: worsening kidney function, especially in patients with pre‑existing renal impairment. - Pulmonary edema: fluid accumulation in the lungs due to rapid volume shifts. - Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity requiring immediate intervention.

When using Mannitol, clinicians should observe several safety measures to minimise complications.

- Assess renal function: monitor serum creatinine and urine output before and during therapy. - Monitor electrolytes: check serum sodium, potassium, and osmolarity regularly. - Adjust infusion rate: use controlled infusion to avoid rapid osmotic shifts. - Caution in cardiac disease: watch for fluid overload and cardiac decompensation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can influence the pharmacodynamics or pharmacokinetics of several agents.

Major Interactions (Avoid): - Loop diuretics: may cause excessive diuresis and profound electrolyte loss. - Insulin: osmotic shifts can potentiate hypoglycaemia, requiring dose adjustment. - ACE inhibitors or ARBs: increased risk of renal impairment when combined.

Moderate Interactions (Monitor Closely): - Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function closely. - Contrast media: heightened risk of contrast‑induced nephropathy. - Lithium: osmotic changes may alter lithium clearance; monitor serum levels.